Amgen (AMGN) data supports long-term growth potential says analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Amgen (AMGN) data supports long-term growth potential says analyst
November 8, 2022 10:20 AM EST
Amgen (NASDAQ: AMGN) Climbs 6.4%
...
More
November 8, 2022 8:16 AM EST
Jefferies analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $325.00 (from $300.00) while maintaining a Buy rating.
The analyst commented, "AMGN update looks positive and consistent w/ our Buy, with valuation likely to go up with AMG-133 for obesity... More
November 8, 2022 8:05 AM EST
Truist Securities analyst Robyn Karnauskas raised the price target on Amgen (NASDAQ: AMGN) to $280.00 (from $266.00) while maintaining a Hold rating.... More
November 8, 2022 8:04 AM EST
Oppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $300.00 (from $290.00) while maintaining an Outperform rating, citing incremental conviction in the Cardiometabolic pipeline.
The analyst commented, "AMGN hosted an investor event post-AHA and provided updated data from Ph3... More
November 7, 2022 4:16 PM EST
Amgen (NASDAQ: AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Nov. 7 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022 in... More
November 7, 2022 9:14 AM EST
UBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $271.00 (from $257.00) while maintaining a Neutral rating.... More
